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Abstract
Cumulative data suggest the involvement of Fyn tyrosine kinase in Alzheimer's 
disease (AD). Previously, our group has shown increased immunoreactivities of 
the FynT isoform in AD neocortex (with no change in the alternatively spliced 
FynB isoform) which associated with neurofibrillary degeneration and reac-
tive astrogliosis. Since both the aforementioned neuropathological features are 
also variably found in Lewy Body dementias (LBD), we investigated potential 
perturbations of Fyn expression in the post-mortem neocortex of patients with 
AD, as well as those diagnosed as having one of the two main subgroups of 
LBD: Parkinson's disease dementia (PDD) and dementia with Lewy bodies 
(DLB). We found selective upregulation of FynT expression in AD, PDD, and 
DLB which also correlated with cognitive impairment. Furthermore, increased 
FynT expression correlated with hallmark neuropathological lesions, soluble 
β-amyloid, and phosphorylated tau, as well as markers of microglia and as-
trocyte activation. In line with the human post-mortem studies, cortical FynT 
expression in aged mice transgenic for human P301S tau was upregulated and 
further correlated with accumulation of aggregated phosphorylated tau as well 
as with microglial and astrocytic markers. Our findings provide further evi-
dence for the involvement of FynT in neurodegenerative dementias, likely via 
effects on tauopathy and neuroinflammation.
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1 |  INTRODUCTION
Alzheimer's disease (AD) and Lewy body dementias 
(LBD) are respectively the number one and two causes 
of neurodegenerative dementia in the elderly, and con-
tribute to significant morbidity for both sufferers and 
their caregivers, as well as to global health-care burden 
(1–3). LBD consists of two clinical subtypes: Parkinson's 
disease dementia (PDD) and dementia with Lewy bodies 
(DLB), where differentiation is mainly based on the “one-
year rule” in which patients presenting with dementia 
before, or within a year of, Parkinsonism symptoms are 
diagnosed as DLB, whereas dementia occurring >1 year 
after Parkinsonism is considered to be PDD (4). While 
PDD and DLB share similar neuropathological features, 
especially the presence of cortical aggregated α-synucle-
in-containing Lewy bodies (LB), significant differences 
in clinical presentation as well as neurochemical pertur-
bations have been reported between them (5–10), giving 
rise to ongoing debate on whether PDD and DLB are 
separate entities or part of the same spectrum of LBD 
(11–14). Interestingly, in addition to LB, both PDD and 
DLB manifest variable burdens of hallmark AD lesions, 
namely intercellular amyloid plaques (AP) consisting 
mainly of insoluble, aggregated β-amyloid peptides (Aβ); 
and intracellular neurofibrillary tangles (NFT) formed 
from aggregation of hyperphosphorylated tau proteins 
into paired helical filaments (15–18). Furthermore, the 
presence of chronic neuroinflammation and glial acti-
vation, which are intimately linked to both AP and NFT 
(19,20), are also salient features of AD and LBD (21,22). 
Therefore, studies focused on the pathophysiological 
mechanisms and effects of AP and NFT formation (23) 
should consider the applicability and implications of 
their findings to LBD.
Given the diverse biological functions (ranging from 
regulating brain function to modulating T-cell signal-
ing) attributed to Fyn, a member of the Src family ty-
rosine kinases (24), it is perhaps unsurprising that Fyn 
kinase has been implicated in AD pathophysiology 
(25). As Fyn is alternatively spliced into two major iso-
forms: brain-predominant FynB and immune cells-pre-
dominant FynT, we have measured FynB versus FynT 
immunoreactivities in post-mortem AD neocortex, 
and found selective increases in FynT which also as-
sociated with neurofibrillary degeneration and reactive 
astrogliosis (26). These findings are in line with in vitro 
data showing that prolonged inflammatory response 
and activation in astrocytes are mediated by pro-in-
flammatory cytokine-induced FynT (27). However, 
the status of Fyn isoform expression as well as poten-
tial associations with neuropathological features and 
neuroinflammatory markers in LBD is currently un-
known. In this study, we identified differential splic-
ing of Fyn using a human transcriptome microarray 
approach, and further confirmed our findings with re-
al-time RT-PCR of Fyn isoform expression in neocortex 
of AD and LBD patients together with aged non-de-
mented subjects, and correlated the measures with Aβ 
and phospho-Tau concentrations, neuroinflammatory 
markers, neuropathological and clinical scores. To fur-
ther study possible links between Fyn perturbations 
and NFT formation, we also monitored longitudinal 
changes of Fyn isoform expression in association with 
tau pathology and neuroinflammation in a transgenic 
mouse model of human tauopathy which harbors the 
human P301S tau mutation (28).
2 |  M ETHODS
2.1 | Patients, clinical and neuropathological 
assessments
Post-mortem brain tissues from the frontal (Brodmann 
Area, BA9, dorsolateral/medial prefrontal cortex) and 
temporal (BA21: middle temporal gyrus) regions of sub-
jects with AD, DLB, PDD, as well as elderly controls 
(CTRL) without neurological or psychiatric diseases 
were obtained from the University Hospital Stavanger, 
Newcastle Brain Tissue Resource, the London 
Neurodegenerative Diseases Brain Bank and the Thomas 
Willis Brain Collections at Oxford University, the UK 
sites being part of the Brains for Dementia Research 
network (29). Subjects with dementia were part of lon-
gitudinal studies and were followed up annually with 
clinical assessments including the Mini-Mental State 
Examination (MMSE) (30) to measure cognitive decline 
until death, at which time informed consent was obtained 
from next-of-kin before removal of brains. Consensus 
criteria used for clinical diagnoses of AD, DLB, and 
PDD with neuropathologic confirmation have been pre-
viously described in detail (31). In addition, semiquan-
titative scoring (0 = None, 1 = Sparse, 2 = Moderate, 
and 3 = Abundant) of AP, NFT/neuropil threads, and 
LB/Lewy neurites as visualized by immunostaining with 
4G8, AT8, and α-synuclein antibodies, respectively, were 
performed by neuropathologists blinded to clinical diag-
nosis as previously described (18). For the neurochemical 
and gene expression studies, 1 cm3 frozen brain chunks 
were obtained from BA9 and BA21 of the hemisphere 
contralateral to the one used for neuropathologic stud-
ies, then, stored at −80°C before further processing for 
homogenate preparation and RNA isolation.
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2.2 | Brain tissues from transgenic mice
The P301S tau transgenic mouse line PS19 (B6 N.Cg-Tg 
(Prnp-MAPT*P301S)PS19Vle/J) were obtained from the 
Jackson Laboratory (Bar Harbor, ME, USA) and bred 
with wild-type (WT) control, C57BL/6  NJ to generate 
hemizygotes and WT littermate controls. The strain har-
bors the 1N4R isoform of human MAPT gene with the 
P301S mutation, driven by mouse prion protein promoter 
which expressed the human P301S tau at levels fivefold 
higher than endogenous mouse tau (28). Brains from 
both genotypes were harvested directly after CO2 eu-
thanasia before 6 months (mo) old (WT: n = 13, 8 M/5F, 
4.9 ± 0.2 mo; P301S: n = 13, 6 M/7F, 4.7 ± 0.2 mo) and 
after 6 months old (WT: n = 18, 10 M/8F, 8.6 ± 0.4 mo; 
P301S: n = 18, 9 M/9F, 8.9 ± 0.4 mo). After removing cer-
ebellum, olfactory bulb, and meninges, the cortex were 
separated into left and right hemispheres for RNA isola-
tion and brain homogenate preparation, respectively. All 
experimental procedures conducted in the study were 
approved by the SingHealth Institutional Animal Care 
and Use Committee and carried out in accordance with 
the approved guidelines and regulations.
2.3 | Brain tissue processing
Unless otherwise specified, all chemicals and reagents 
were purchased from Sigma Aldrich (St Louis, MO, 
USA) and of analytical grade. Frozen human brain 
chunks from BA9 and BA21 were thawed on ice, dis-
sected free of meninges and white matter, then, homog-
enized (21) with an Ultra-Turrax® T-25 homogenizer 
(IKA-Werke, Staufen, Germany) in ice-cold buffer 
(50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, and pH 
7.4) with cOmplete™ protease inhibitor cocktail and 
PhosSTOP™ phosphatase inhibitor tablets (Roche Life 
Science, Penzberg, Germany). Brain homogenates from 
mice were prepared as above without the prior dissec-
tion step. For both human and mice brains, representa-
tive portions were kept in TRIzol® reagent (Invitrogen 
Inc., Carlsbad, CA, USA) at −80°C for subsequent 
RNA extraction.
2.4 | Enzyme-linked immunosorbent assays 
(ELISA) of pS396 Tau and soluble Aβ42 in 
human neocortex
Aliquots of brain homogenates was treated with 5 M 
Guanidine for detection of tau with serine phospho-
rylation at position 396 (pS396 Tau) by ELISA accord-
ing to manufacturer's instructions (KHB7031, Thermo 
Fisher Scientific, Waltham, MA, USA). Separate ho-
mogenate aliquots were agitated using a sonicator for 
30 mins at 4°C before centrifugation at 6000 g, 30 min 
at 4°C, with the supernatant used for detection of 
soluble Aβ1-42 peptides (sAβ42) by ELISA according to 
manufacturer's instructions (KHB3441, Thermo Fisher 
Scientific). Concentrations values in pg/mL were nor-
malized to protein content of each sample (determined 
using Pierce Coomassie Plus Reagent, Thermo Fisher 
Scientific) and presented as pg/mg protein.
2.5 | RNA isolation, reverse transcription 
polymerase chain reaction (RT-PCR), and 
capillary electrophoresis
Brain tissue kept frozen in TRIzol® reagent (Invitrogen 
Inc., Carlsbad, CA, USA) were thawed and processed 
for RNA extraction following manufacturer's instruc-
tions. A Fragment Analyzer™ system (Advanced 
Analytical Technologies Inc, Ankeny, IA, USA) was 
used for evaluating RNA quality, with RIN <3.0 ex-
cluded from further analysis. 2 μg of RNA was reverse-
transcribed to cDNA using High-Capacity cDNA RT 
kit (Applied Biosystems, Foster City, CA, USA) in ac-
cordance to manufacturer's protocol. Semiquantitative 
measurements of gene expression were performed on the 
7500 Fast Real-time PCR system (Applied Biosystems) 
or CFX96  TM Real-time PCR system (BioRad) using 
GoTaq® qPCR Master Mix (Promega, Madison, WI, 
USA). The primer sequences used in this study are 
listed in Table S1. All real-time RT-PCR assays were 
performed in duplicate. Standard curves of each gene 
were generated independently by 10x serial dilution of 
template DNA. The relative signal intensity of each 
sample was calculated according to the corresponding 
standard curve. Normalization was performed in each 
sample by dividing the relative signal intensity of gene 
of interest to geometric mean of β-actin, GAPDH, and 
18S rRNA. To determine FynT to FynB ratios using 
capillary electrophoresis, a pair of common prim-
ers spanning the alternative spliced exon of Fyn were 
used as described previously (26). Peak areas of FynT 
(219 bp DNA amplicon) and FynB (228 bp DNA am-
plicon) in each electropherogram were translated into 
expression level and used to determine ratios of FynT 
to FynB expression.
2.6 | Human Transcriptome Array 
(HTA) data and Gene Ontology (GO) term 
enrichment analyses
A subset of samples (9 CTRL, 9 AD, 12 DLB, and 12 
PDD) from BA9 were processed for high-throughput 
transcriptome profiling using the GeneChip® HTA 
2.0 array (Affymetrix, Santa Clara, CA, USA). The 
data set has been deposited with the Gene Expression 
Omnibus (GEO) (Access #GSE15 0696). Using the Gene 
View module of Partek Genomics Suite® 7.0 software 
(Partek Inc, St Louis, MO, USA), we were able to 
256 |   LOW et aL.
allocate differentially expressed probesets to specific 
transcript variants of Fyn. Expressed probesets which 
were significantly correlated with the FynT-specific 
probesets (PSR06025242.hg.1) at false discovery rate 
(FDR)(32) cutoff of 5% were retrieved. Genes with ≥10 
representative probesets that consistently correlated 
with FynT were subject to Gene Ontology (GO) term 
enrichment analyses using DAVID Bioinformatics 
Resources 6.7 (http://david.abcc.ncifc rf.gov/) (33,34), 
with Benjamini's enrichment p values adjustment for 
multiple testing using FDR of 5%. For this study, we 
focused on GO categories of Biological Processing 
and Cellular components, after removing general GO 
terms with enrichment factor <2.
2.7 | Homogenous Time-Resolved 
Fluorescence (HTRF) assays of mouse brain 
homogenates
Cisbio® HTRF assays (PerkinElmer Inc. Waltham, 
MA, USA), a technology combining standard fluores-
cence resonance energy transfer (FRET) with time-
resolved measurement of f luorescence, were used for 
measuring total human tau protein (MAP-Tau Kit), 
phosphorylated tau (Phospho-Ser202/Thr205 human 
TAU kit), and aggregated tau (Tau aggregation kit) 
according to manufacturer's instructions. A portion 
of the right hemisphere was homogenized in Cisbio 
lysis buffer with blocking reagent using 5  mm stain-
less steel beads in a TissueLyser LT (Qiagen, Venlo, the 
Netherlands) tissue disruptor (two rounds of 50  Hz, 
2 min). After centrifugation at 21,000 g for 20 min at 
4°C, supernatants were measured for protein concen-
tration using the Bradford protein assay kit (BioRad, 
Hercules, CA, USA). Equal amounts of brain homoge-
nate were then diluted and incubated with respective 
antibodies for 24 h at room temperature. Samples were 
excited at 340  nm and emission values collected at 
620 nm (Donor) and 665 nm (Acceptor) using EnSpire® 
multimode plate reader (Perkin Elmer). For data analy-
sis, HTRF ratio was calculated for each individual well 
by the ratio of the two emission values (Signal 665 nm/
Signal 620 nm) and multiplied by 10,000 to ease data 
processing. Data were presented as Delta F% which 
reflected the signal to background of the assay, and 
calculated as [HTRF ratio (sample) - HTRF ratio (neg-
ative control)]/HTRF ratio (negative control) x 100.
2.8 | Statistical analyses
Pairwise differences among groups were analyzed by 
Kruskal–Wallis analysis of variance (ANOVA) with post 
hoc Dunn's test or data transformed to log2 base value 
and analyzed using one-way ANOVA with Bonferroni's 
post hoc tests. Two-way ANOVA with Bonferroni's post 
hoc tests were applied to transgenic mice study with 
genotype and age as independent variables. Pearson's or 
Spearman's correlations was used to for parametric or 
nonparametric variables, respectively. For all analyses, 
two-tailed p values of <0.05 were considered to be sta-
tistically significant. Statistical analyses and plotting of 
graphs were performed using the PRISM Version 5 soft-
ware (GraphPad, San Diego, CA, USA).
3 |  RESU LTS
3.1 | Demographic and disease variables of 
the study cohort
Table 1 shows the maximum available numbers of aged 
controls (CTRL) as well as a community-based cohort of 
PDD, DLB, and AD patients. Groups were not signifi-
cantly different in age at death and post-mortem interval 
(Kruskal–Wallis ANOVA p > 0.05). Within the demen-
tia subgroups (AD, PDD, and DLB), no significant 
difference in dementia severity (indicated by MMSE de-
cline per year) was observed (Kruskal–Wallis ANOVA 
p  >  0.05). Braak staging (35) for extent of AD patho-
logical changes showed all but one of the aged CTRL in 
Braak stage ≤II, with one in III–IV (another four CTRL 
did not have Braak staging data). In contrast, 10 out of 
13 available AD cases were Braak V/VI, with the rest 
in Braak III/IV. PDD and DLB showed variable AD 
pathology ranging from Braak ≤II to V/VI, with DLB 
showing higher numbers of those with more advanced 
stages compared to PDD. Furthermore, ELISA meas-
ures of sAβ42 and pS396Tau, used respectively as mark-
ers of amyloid and neurofibrillary tangle burden, were 
also raised in the dementia subgroups, with the highest 
levels in AD, and the lowest in PDD (Table 1). These 
neuropathological and biochemical features are in line 
with previous clinical and post-mortem observations of 
AD and Lewy body dementias, especially with regards 
to PDD harboring the lowest AD pathological burden 
among the dementia subgroups (17,18).
3.2 | Selective upregulation of FynT isoform 
expression in neocortex of AD and LBD
We have previously reported specific increases of FynT 
immunoreactivities which contrasted with unchanged 
brain-predominant FynB in AD (26). Here, using a 
high-throughput gene profiling (HTA) platform, we 
found similar FynT upregulation in a separate cohort of 
AD and further extended this observation to DLB and 
PDD. Figure 1 shows Gene View plot where probeset 
PSR06025242.hg.1 (indicated by blue asterisk) corre-
sponding to sequence for FynT-specific exon was sig-
nificantly upregulated in AD (~3 fold), DLB (~2.5 fold), 
and PDD (~1.8 fold) prefrontal cortex compared with 
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CTRL AD DLB PDD
(n = 16) (n = 13) (n = 39) (n = 27)
Demographicsa 
Gender (male/female) 9 M/7F 5 M/8F 26 M/13F 15 M/12F
Age at death (years) 82.0 ± 1.7 86.1 ± 1.9 80.9 ± 1.1 79.3 ± 1.2
Postmortem interval (hours) 45.7 ± 5.9 36.7 ± 7.1 43.7 ± 4.9 33.5 ± 3.0







0–II 11 (91.7%) 0 (0%) 6 (15.4%) 18 (66.7%)
III–IV 1 (8.3%) 3 (23%) 20 (51.3%) 7 (26%)
V–VI 0 (0%) 10 (77%) 13 (33.3%) 2 (7.3%)
ELISA assay


































Data are presented as mean ± S.E.M.
aMaximum available n. Not all samples were available for all assessments. Available n listed in individual 
assessments. 
*Significantly different compared to CTRL (Kruskal–Wallis ANOVA with post hoc Dunn's test, p < 0.05). 
**Significantly different compared to AD (Kruskal–Wallis AONVA with post hoc Dunn's test, p < 0.05). 
***Significantly different compared to DLB (Kruskal–Wallis ANOVA with post hoc Dunn's test, p < 0.05). 
TA B L E  1  Demographic and disease 
variables of a cohort of patients with 
neuropathologically confirmed AD and 
LBD
F I G U R E  1  Specific upregulation of FynT isoform expression in prefrontal cortex of AD and LBD. Gene View plot demonstrates 
differential alternative splicing of Fyn in BA9 samples of CTRL (n = 9, red), AD (n = 9, blue), DLB (n = 12, amber), and PDD (n = 12, green), 
from data derived from Affymetrix HTA array. Light blue asterisk indicated the PSR06025242.hg.1 probeset, with a magnified view shown 
in the inset, corresponding to the FynT-specific exon highlighted in blue. FynB-specific exons are highlighted in yellow. The Y-axis is in Log2 
scale intensity value. The p values shown are of Alt-splicing ANOVAs using the Partek Genomic Suite® software [Colour figure can be viewed 
at wileyonlinelibrary.com]
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CTRL. In contrast, probesets corresponding to com-
mon exons and FynB-specific exons (yellow boxes in 
FynB transcript, Figure 1) showed no significant induc-
tion in the dementia subgroups. To confirm these find-
ings, we determined the proportional amounts of FynB 
and FynT in two brain regions (BA9 and BA21) of aged 
CTRL and dementia subgroups using common primers 
spanning the alternative spliced exon of Fyn for RT-PCR 
followed by capillary electrophoresis. The representa-
tive electropherograms in Figure 2A indicated that the 
FynT peaks were about 10 times lower than FynB peaks 
in CTRL, while elevations of FynT peaks relative to 
FynB were detected in the dementia subgroups. Indeed, 
AD, DLB, and PDD all had significantly higher FynT 
to FynB ratios compared to CTRL in both BA9 and 
BA21 (Figure 2B), with the ratios showing a high degree 
of correlation between the two brain regions (Pearson's 
r = 0.79, p < 0.001).
3.3 | FynT upregulation correlated with 
cognitive impairment and neuropathological 
features in AD and LBD
In order to investigate potential associations between Fyn 
perturbations and clinical or neuropathologic features, 
FynT and FynB expression levels were determined by 
real-time RT-PCR and correlated with pre-death MMSE, 
neuropathologic scores as well as sAβ42 and pS396 Tau 
concentrations. Consistently, FynT was observed to be 
upregulated in the dementia subgroups, reaching statisti-
cal significance for AD and DLB (with a trend toward 
increase for PDD) in BA9, and for all three dementia sub-
groups in BA21 (Figure 3A left panel). We also confirmed 
that FynB expression were not significantly altered in the 
dementia subgroups (Figure 3A right panel).
Figure 3B shows that FynT expression in both BA9 
and BA21 negatively correlated with pre-death MMSE 
scores in the combined dementia cohort, suggesting that 
FynT upregulation may be associated with more severe 
cognitive impairment. Furthermore, Figure 3C lists the 
correlation coefficients between Fyn expression and (i) 
semiquantitative scores of amyloid plaques, neurofibril-
lary tangles (NFT), Lewy bodies (LB), and combined 
neuropathologic scores (which we have previously shown 
to be variably increased in LBD (18)); (ii) Braak staging 
and (iii) concentrations of soluble Aβ (sAβ42) and phos-
phorylated Tau (pS396 Tau). Interestingly, FynT ex-
pression was widely correlated with neuropathological 
scores (NFT, LB, and combined scores), Braak stage, 
sAβ42 and pS396 Tau measures, especially in BA9, while 
FynB did not correlate with neuropathologic scores 
F I G U R E  2  Increased FynT to FynB 
ratios in prefrontal and temporal cortex 
of AD and LBD. (A) Representative 
electropherograms of the proportional 
levels of FynB and FynT in each sample 
as determined by RT-PCR using common 
primers spanning the alternatively 
spliced exon of Fyn followed by capillary 
electrophoresis. Relative fluorescence 
units (RFU) of FynT peak (219 bp DNA 
amplicon) and FynB peak (128 bp DNA 
amplicon) are shown for each diagnostic 
group. (B) Peak areas of FynT and 
FynB in each electropherogram were 
converted to gene transcript levels and 
used to determine ratio of FynT to FynB 
expression, depicted as dot plots of CTRL 
(n = 14, red), AD (n = 13, blue), DLB 
(n = 18, amber), and PDD (n = 19, green) 
values with horizontal lines in each group 
indicating median and interquartile 
range. *p < 0.05, **p < 0.01, ***p < 0.001, 
significantly different from CTRL by 
Kruskal–Wallis ANOVA with post hoc 
Dunn's tests [Colour figure can be viewed 
at wileyonlinelibrary.com]
   | 259FYNT IN TAUOPATHY OF AD AND LBD
and biochemical measures except for Braak stage and 
pS396 Tau in BA9 (Figure 3C). Taken together, our data 
suggest that FynT isoform-specific upregulation in the 
neocortex may be associated with clinical severity and 
neuropathological burden in AD and LBD.
3.4 | FynT upregulation correlated with 
markers of neuroinflammation in AD and LBD
We have previously found that FynT induction was associ-
ated with astrocyte activation under neuroinflammatory 
conditions (27). In PD, microglial activation was also re-
ported to be dependent on Fyn kinase activity (36). Here, 
we investigated potential associations between Fyn ex-
pression and neuroinflammatory responses using glial 
fibrillary acidic protein (GFAP) and CD11b expression to 
indicate astrogliosis and microglial activation, respectively 
(37,38). Figure 4A shows significant increases of GFAP 
expression in BA9 for AD, and in BA21 for DLB, while 
expression remained unchanged for PDD in both regions 
(left panel). For microglia marker CD11b, expression was 
significantly increased in BA9 for AD, and in BA21 for all 
dementia subgroups (right panel). Figure 4B indicates that 
F I G U R E  3  FynT upregulation in AD and LBD correlates with cognitive impairment and neuropathological features. (A) FynT and FynB 
expression were determined by real-time RT-PCR in BA9 and BA21, derived from CTRL (n = 13–15, red), AD (n = 11–12, blue), DLB (n = 25–
31, amber), and PDD (n = 14–21, green). Data were Log2 transformed and depicted as box plots, with the horizontal intersecting lines and 
borders indicating median and interquartile range for each group, while whiskers show the highest and lowest values not considered outliers. 
(B) Scatter plots of Log2-transforemd FynT expression against pre-death cognition (MMSE) scores in BA9 (left) and BA21 (right) in the 
combined dementia cohort. Solid lines indicated linear regressed best-fit curves while dashed lines indicated their respective 95% confidence 
intervals, with insets showing Pearson's correlation coefficients (r) and their respective p values. (C) Table of correlation coefficients for FynT 
or FynB expression with neuropathologic scores, Braak stage and biochemical measures of pS396Tau and soluble Aβ42 (in pg/mg protein) were 
analyzed using samples derived from CTRL, AD, and LBD. **p < 0.01, ***p < 0.001, significant differences compared to CTRL by one-way 
ANOVA with post hoc Bonferroni's tests. ¶Pearson's (r) and §Spearman's (ρ) correlation coefficients with p < 0.05 [Colour figure can be viewed at 
wileyonlinelibrary.com]
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FynT expression correlated with both GFAP and CD11b in 
both brain regions in the combined cohort. To study poten-
tial sources of Fyn isoform expression in brain, we meas-
ured FynT to FynB ratios, as well as FynT, FynB, GFAP, 
and CD11b expression in isolated rat primary astrocyte, 
microglia, and neurons. Among the three cell types, we 
observed the highest expression of FynT in microglia, fol-
lowed by astrocytes, with neurons showing the lowest ex-
pression (see Figure S1). Taken together, our results suggest 
that FynT induction has a role in astrogliosis and micro-
glial activation in the neocortex of AD and LBD.
3.5 | Synaptic dysfunction is a potential 
consequence of FynT upregulation in 
AD and LBD
To investigate the potential pathophysiological impact 
of FynT induction in neurodegenerative dementias, we 
utilized the high-throughput transcriptome profiling 
data on BA9 of a subset of the cohort (9 CTRL, 9 AD, 
12 DLB, and 12 PDD). The subset was selected based on 
RNA quality (RIN > 4) and matched demographic fac-
tors (gender, age, and PMI), and not on neuropathologi-
cal scores or neurochemical variables. Stringent criteria 
(see details in methodology) were set to identify candi-
date genes which were correlated either positively or 
negatively with FynT. In summary, 515 FynT-positively 
correlated genes and 1437 FynT-negatively correlated 
genes were uncovered and independently analyzed by 
DAVID (34) to gain an overview of the functional pro-
files of associated genes in order to understand the un-
derlying processes. Table 2 summarizes the top five GO 
(gene ontogeny) terms found in each category (the full 
list of GO terms and corresponding genes can be found 
in Table S2). In general, genes positively correlated with 
FynT were mainly associated with cell adhesion, whereas 
the negatively correlated genes were associated with 
F I G U R E  4  Association of FynT expression with neuroinflammatory markers in CTRL, AD, and LBD. (A) Gene expression of GFAP 
astrocytic marker (left) and CD11b microglial marker (right) were determined by real-time RT-PCR in BA9 and BA21, derived from CTRL 
(n = 13–15, red), AD (n = 11–12, blue), DLB (n = 25–31, amber), and PDD (n = 14–21, green). Data were Log2 transformed and depicted as box 
plots, with the horizontal intersecting lines and borders indicating median and interquartile range for each group, while whiskers show the 
highest and lowest values not considered outliers. (B) Scatter plots of Log2-transforemd FynT expression against GFAP (left) and CD11b (right) 
in BA9 (top) and BA21 (bottom) of the combined cohort. Solid lines indicated linear regressed best-fit curves while dashed lines indicated their 
respective 95% confidence intervals, with insets showing Pearson's correlation coefficients (r) and their respective p values. *p < 0.05, **p < 0.01, 
***p < 0.001, significant pairwise differences between diagnostic groups by one-way ANOVA with post hoc Bonferroni's tests [Colour figure can 
be viewed at wileyonlinelibrary.com]
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neuronal function and components found in dendrites 
and synapses (Table 2). These results suggest that synap-
tic dysfunction and synaptopathology may be associated 
with FynT upregulation in AD and LBD.
3.6 | Selective upregulation of FynT is  
associated with tauopathy and 
neuroinflammation in aged P301S mice
Finally, the potential pathophysiological links between 
FynT induction, tau pathology, and neuroinflammation 
were studied in a P301S Tau transgenic mouse model of 
tauopathy at two age groups: <6 mo when there is minimal 
brain pathology; and ≥6 mo, when the mice are known to 
manifest neurofibrillary tangles and neuroinflammation 
during disease progression. HTRF assays confirmed that 
P301S Tau mice expressed high levels of human tau in the 
brain when compared with wild-type (WT) littermate con-
trols at both age groups (Figure 5A, left panel). However, 
the younger P301S mice (<6 mo) showed minimal phos-
phorylated tau and aggregation, similar to WT (Figure 5A, 
middle and right panels). In contrast, older mice (≥ 6 mo) 
showed significantly increased levels of phosphorylated, 
aggregated tau (Figure 5A, middle and right panels). 
Similar to observations of human post-mortem brains, 
we found significantly increased FynT expression as well 
as higher FynT to FynB ratio in older, but not younger, 
P301S mice (Figure 5B left and right panels), while FynB 
expression was unchanged in both age groups (Figure 5B 
middle panel). Furthermore, markers of neuroinflamma-
tory responses as indicated by GFAP and CD11b expres-
sion were significantly increased only in older P301S mice 
(Figure 5C). Finally, Figure 5D lists the correlation coef-
ficients between expression of Fyn isoforms, GFAP and 
CD11b as well as HTRF measurements of phosphoryl-
ated and aggregated Tau, and showed that both FynT and 
FynT:FynB correlated with the neuroinflammatory mark-
ers as well as pathologic Tau markers. Therefore, our find-
ings suggest that selective FynT upregulation likely occurs 
downstream of tauopathy and is associated with disease 
progression, including neuroinflammation, in P301S mice.
4 |  DISCUSSION
4.1 | FynT kinase as a potential mediator of 
tauopathy
While processes associated with amyloid precursor 
protein mismetabolism leading to accumulation of in-
soluble Aβ plays a major role in AD pathogenesis (39), it 
TA B L E  2  Top five* GO Terms under BP and CC categories for FynT positively and negatively correlated genes derived from CTRL, AD, 
and LBD transcriptome profiling data
GO term ID (categories)
Description (FynT positively correlated 
genes) Counta Fold enrichmentb Benjaminic 
GO:0005913 (CC) Cell–cell adherens junction 34 4.07 2.64E-09
GO:0005925 (CC) focal adhesion 37 3.66 4.69E-09
GO:0030027 (CC) lamellipodium 18 4.35 5.62E-05
GO:0030175 (CC) filopodium 12 6.54 9.64E-05
GO:0001726 (CC) ruffle 13 5.59 1.53E-04
GO:0098609 (BP)* Cell–cell adhesion 24 3.23 4.00E-03
GO:0016569 (BP)* covalent chromatin modification 14 4.51 1.52E-02
GO term ID (categories)
Description (FynT negatively correlated 
genes) Counta Fold enrichmentb Benjaminic 
GO:0043209 (CC) myelin sheath 54 4.75 3.64E-20
GO:0030054 (CC) cell junction 91 2.65 1.62E-15
GO:0014069 (CC) postsynaptic density 50 3.64 2.66E-13
GO:0008021 (CC) synaptic vesicle 33 4.80 5.41E-12
GO:0045211 (CC) postsynaptic membrane 49 3.11 2.28E-10
GO:0016192 (BP) vesicle-mediated transport 40 3.41 2.46E-08
GO:0034220 (BP) ion transmembrane transport 48 2.96 2.57E-08
GO:0006886 (BP) intracellular protein transport 52 2.85 4.34E-08
GO:0000165 (BP) MAPK cascade 54 2.67 6.03E-08
GO:0016241 (BP) regulation of macroautophagy 20 5.88 1.06E-07
Gene ontology (GO) category: biological process (BP) and cellular component (CC).
aCount represents the total number of genes correlated with FynT in the respective GO term. 
bFold enrichment is used to measure the magnitude of enrichment. 
cp values adjusted for multiple testing using FDR < 0.05. 
*For FynT positively correlated genes, only two BP terms were significant at FDR < 0.05. 
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is the hyperphosphorylation of tau and ensuing forma-
tion of neurofibrillary tangles (NFT) which correlated 
more closely with disease progression, and may indeed 
mediate the clinical severity of AD (40,41). As NFT (to-
gether with amyloid plaques) are a common feature of 
AD, PDD, and DLB, these neurodegenerative demen-
tias can be defined as tauopathies. In this paper, we 
reported further evidence for a selective upregulation 
of the FynT isoform in AD neocortex, and extended 
these observations to PDD and DLB. As basal FynT 
expression was around one tenth of FynB expression 
in the normal brain (see Figure 2), we speculate that 
the inability of some previous studies to detect Fyn in-
duction in AD (42,43) was likely because of the use of 
non-isoform-specific measurements, since the amount 
of FynT increase would likely be masked by the un-
changed, predominant FynB isoform. Importantly, 
we showed here that FynT upregulation was associ-
ated with astrogliosis, microglial activation, neuro-
pathologic burden, and dementia severity, therefore, 
suggesting, as others have (25), that Fyn may mediate 
the pathophysiological link between amyloid and tau. 
Indeed, Fyn can regulate Aβ-induced excitotoxicity by 
interacting with dendritic tau, the latter targeting Fyn 
F I G U R E  5  Selective upregulation of FynT in aged transgenic P301S tau mice correlates with tauopathy and neuroinflammation. (A) 
Determination of phosphorylated tau (pS202/T205 tau), aggregated tau and total tau protein by HTRF in the brain homogenates of P301S Tau 
transgenic mice and wild-type littermate controls at age <6 mo (before onset of pathology, labels in small letters: p301 s, wt) and ≥6 mo (with 
disease progression, labels in capital letters: P301S, WT). RT-PCR derived values for relative expressions of (B) FynT, FynB (together with FynT 
to FynB ratios) as well as (C) GFAP and CD11b in the samples as described above. Horizontal lines on the dot plots in each group indicate 
median and interquartile range. (D) Table of correlation coefficients for FynT, FynB, FynT:FynB with phosphorylated tau, aggregated tau, and 
neuroinflammation markers. *p < 0.05, **p < 0.01, ***p < 0.001, significant pairwise differences by two-way ANOVA with post hoc Bonferroni's 
tests (Significance of the Genotype, Age, and Interaction factors are given in the respective insets of each graph). ¶Pearson's (r) correlation 
coefficients with p < 0.05 [Colour figure can be viewed at wileyonlinelibrary.com]
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postsynaptically to glutamate NMDA receptors where 
excitotoxic signals are transmitted (44). Aβ-induced 
tau accumulation at somatodendritic compartments 
was also found to be Fyn-dependent (45). In another 
study, binding of Aβ oligomers to postsynaptic prion 
proteins was shown to trigger Fyn-mediated signal-
ing cascades leading to tauopathy and synaptotoxicity 
(46,47). Interestingly, more recent studies suggest that 
Fyn can also be a key regulator of tau-associated pa-
thology in the absence of Aβ (48–50). Conversely, tau 
seem to directly regulate Fyn targeting to (44); and 
nanodomain organization (51) within, neuronal den-
drites. The complex interactions between Fyn and tau 
have been further demonstrated by tau's induction of 
Fyn autophosphorylation and kinase activity (52), con-
trasting with Fyn-mediated direct (on tyrosine18) (53) 
and indirect (via CDK5 and GSK3) (54,55) phospho-
rylation of tau. In summary, Fyn seems to be able to 
signal to tau and regulate tau-associated pathology in 
both Aβ-dependent and -independent pathways. Our 
own observations of FynT upregulation and correla-
tions with tauopathy in AD and LBD, as well as FynT 
changes in P301S mice which do not manifest Aβ bur-
den, suggest that Fyn interacts with tau in these condi-
tions in an isoform-specific manner, and that at least 
some of the pathogenic mechanisms mentioned above 
may be mediated by altered regulation of alternative 
splicing which favors FynT.
4.2 | Potential mechanisms of FynT-
associated neuronal dysfunction and 
neuroinflammation in AD and LBD
Several studies have demonstrated that Fyn kinase can 
modulate synaptic plasticity and learning (56–59). In this 
study, we speculated that the detrimental consequences 
of FynT upregulation during the dementia progression 
could be associated with synaptic dysfunction, based on 
the consistent negative correlations of FynT with genes 
coding for functional components of neurons and syn-
apses (Table 2), as well as with pre-death cognitive scores 
(Figure 3B). Recently, mutant P301L tau has been shown 
to promote aberrant Fyn nanoclustering in dendritic 
spines which likely contributes to synaptic dysfunction 
(51). In this study, we used a similar mutant P301S tau 
mice to demonstrate that age-dependent increment of 
phosphorylated and aggregated tau was associated with 
FynT upregulation (Figure 5). Interestingly, while per-
turbations of neuronal networks and long-term poten-
tiation have been reported in young (2 month old) mice 
(60), our data suggest that these processes are unlikely to 
involve FynT changes, since FynT upregulation was not 
apparent until 6  months or older (Figure 5B). Instead, 
FynT might mediate the previously reported contribu-
tions of tau pathology to the development of chronic in-
flammatory responses during reactive astrogliosis (61). 
We have reported increased FynT immunoreactivity in 
hypertrophic cytoplasm of reactive astrocytes in the AD 
brain (27), which is corroborated here by the finding of 
significant correlations between FynT and GFAP ex-
pression (Figures 4B and 5D).
Additionally, Fyn induction in post-mortem PD 
brains has been reported to be associated with neuroin-
flammatory responses resulting from microglial activa-
tion (62). Interestingly, the present in vitro data indicate 
the highest expression of FynT in microglia, followed by 
astrocyte, while neurons had the lowest expression (see 
Figure S1). As the correlation coefficient for FynT and 
CD11b expression was higher than those between FynT 
and GFAP or pS396Tau in the post-mortem study, our 
data suggest FynT upregulation in the AD and LBD 
brain could due in large part to activation of predom-
inantly FynT-expressing microglia, which may in turn 
contribute to chronic neuroinflammation-associated 
neuronal damage (63). However, given the significant (al-
beit weaker) correlations between FynT and GFAP, as 
well as previously reported localization of FynT in reac-
tive astrocytes (26), we postulate that astrogliosis under-
lie at least part of the observed FynT upregulation. Here, 
it is worth noting that FynT likely plays a critical role in 
astrocyte activation, as we have previously shown that 
neuroinflammatory responses to tumor necrosis factor is 
abolished in astrocytes expressing a kinase-dead mutant 
of FynT (27). Therefore, when considered in the context 
of previous studies, our current in vitro and post-mortem 
data suggest that in AD and LBD, FynT upregulation 
likely occurs in response to tau phosphorylation and 
NFT formation, and mediates astrocyte and/or microg-
lial activation, leading in turn to neuroinflammation-as-
sociated synaptic dysfunction and neuronal damage.
4.3 | Isoform-specific 
role of FynT as therapeutic target for 
neurodegenerative dementias
Fyn kinase has already been proposed as a potential 
therapeutic target for AD (64). In this regard, a previ-
ous study showed that inhibiting Fyn in an AD mouse 
model restored synaptic density, limited tau aggrega-
tion, reduced microglial activation, and subsequently 
reversed memory deficits without attenuating Aβ load 
(58). Recent findings consistently demonstrated that 
both pharmacological Fyn inhibition and depletion of 
Fyn (via gene knockout) in tauopathy models resulted 
in behavioral improvements, recovery of synaptic loss, 
together with reduced tau phosphorylation and gliosis, 
suggesting that Fyn is an essential pathogenic factor in 
tauopathies (48–50). This has expanded the application 
of Fyn as a therapeutic target for tauopathies in addi-
tion to AD. However, it is worth noting that AZDO530, 
a Src family kinase inhibitor which showed promise in 
animal studies, demonstrated no statistically significant 
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improvement on neuroimaging outcome in AD patients 
in a year-long Phase IIa clinical trial (although a trend 
toward less shrinkage of the hippocampus and entorhi-
nal cortex was observed in the treated group)(65). One 
insight that may be gleaned from our study is the need 
to refine the target to Fyn, and specifically the FynT 
isoform, for potentially improved efficacy as well as re-
duced off-target adverse effects, since the major brain 
variant FynB has important physiological functions 
and should not be targeted. Furthermore, when a FynT-
specific compound does become available, our data 
suggest extending assessments of their clinical utility to 
LBD in addition to AD.
4.4 | Study limitations
There are several limitations apparent in this study 
which are related to the limited number of available 
samples. Therefore, in interpreting findings where 
changes are found in one, but not both of the brain re-
gions examined (e.g., significant correlation between 
FynT and neurofibrillary tangle (NFT) scores in BA9 
prefrontal cortex but not BA21 temporal cortex, see 
Figure 3C), it is unclear whether the observed regional 
differences has a genuine pathophysiological basis (for, 
e.g., more active disease process in BA9 versus wide-
spread cell loss in BA21(66)) or was because of higher 
data variability in BA21 resulting in nonsignificance 
of the association. On the contrary, FynT expression 
seemed to be increased in both regions in LBD, but 
did not reach statistical significance in BA9 for PDD 
(Figure 3A). While higher AP and NFT loads are de-
tected in DLB compared with PDD (12,67), and NFT 
(which we have shown here to be strongly correlated 
with FynT) is known to originate from the entorhinal, 
hippocampal, and neocortical regions of the temporal 
lobe followed by progression into the prefrontal and 
other neocortical areas (68), we cannot at present con-
firm whether these regional differences are DLB- or 
PDD-specific because of associations with pathologi-
cal burden, necessitating follow-up studies on larger 
cohorts looking at multiple brain regions.
Second, the current study has not studied Fyn as-
sociations with LBD-specific lesions (α-synuclein-con-
taining Lewy bodies, LB) in detail. While the focus of 
our study has been on AD pathological features which 
are present in both AD and LBD, FynT may also be 
linked to LB, as suggested by Figure 3C. However, it 
is at present unclear whether, or how, FynT may be 
related to α-synuclein aggregation and related patho-
physiology per se, as assays of soluble α-synuclein re-
vealed unchanged baseline cortical concentrations 
across controls and dementia subgroups in agreement 
with previous studies (69,70) which did not correlate 
with Fyn or other neuropathological measures (data 
not shown). These negative findings suggest that other 
potentially pathogenic species of α-synuclein, for ex-
ample, Ser129-phosphorylated α-synuclein (71) need to 
be measured in follow-up studies of potential Fyn in-
volvement in LBD-specific pathology.
Finally, the current study employed a genomics ap-
proach with the use of microarrays and RT-PCR to 
study Fyn expression and associations with a wide range 
of gene expression changes. There is therefore a lack of 
histological and cellular localization data, which is mit-
igated somewhat by (i) the use of primary cultures to 
provide in vitro validation of the likely sources of FynT, 
namely, astrocytes and microglia (Figure S1); and (ii) our 
previous study which showed the localization of FynT 
in activated astrocytes in AD (26). However, follow-up 
studies are needed to confirm the findings for microglia 
and also extend them to LBD.
5 |  CONCLUSIONS
Using microarray platforms, we report FynT isoform-
specific upregulation in the neocortex of AD, DLB, 
and PDD. The observed induction of FynT was closely 
associated with tauopathy and neuroinflammation, 
and may mediate their deleterious effects on synap-
tic and cognitive functions. In corroboration, age-
dependent FynT upregulation was detected in P301S 
mutant tau transgenic mice, which was significantly 
correlated with phosphorylated and aggregated tau, 
as well as with markers of microglial and astrocytic 
activation. Our findings point to FynT as the patho-
genic Fyn isoform for AD and LBD, and propose a 
refinement of therapeutic approach from nonspe-
cific inhibition of Src family kinases to a more fo-
cused search for compounds which specifically target 
FynT as potential treatment for AD-related chronic 
neuroinflammation.
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